Literature DB >> 2785863

Biological response modifier as antigen: OK432-specific T-cell clone as an anti-tumor effector cell.

S Ozaki1, T Suginoshita.   

Abstract

OK432, a Streptococcus preparation, is a biological response modifier that has been used in the treatment of malignant diseases. A cloned Thy 1.2+, L3T4+, Lyt 2.2- T cell (OK2.21), specific for OK432 and restricted to I-Ed, was isolated from BALB/c mice immunized with OK432. OK2.21 not only secreted interleukin 2 but also killed Iad-bearing B-lymphoma cells in an antigen-specific manner. The clone also killed Ia-negative bystander tumor targets, but only in the presence of both OK432 and antigen-presenting cells. Despite the cytotoxicity against tumor cells, OK2.21 did not kill OK432-pulsed normal spleen cells. Injection of this clone together with OK432 to tumor-bearing BALB/c mice prolonged their survival, suggesting that this clone acts as an anti-tumor effector (or effector-inducer) cell in the therapy with OK432.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785863     DOI: 10.1016/0008-8749(89)90215-3

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice.

Authors:  Y Moriya; H Sato; K Ito; M Saito; T Yoshida; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

2.  Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner.

Authors:  S Ozaki; T Okazaki; K Nakao
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

3.  Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy.

Authors:  Y Katsumoto; T Monden; T Takeda; A Haba; Y Ito; E Wakasugi; T Wakasugi; M Sekimoto; T Kobayashi; H Shiozaki; T Shimano; M Monden
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.